Share

    


In This Section

Home / News & Media / Educational Resources

Educational Resources

These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email CorporateRelations@accc-cancer.org for assistance.
  • A Toolkit For Those Living With or Care For Someone with Diffuse Large B-Cell Lymphoma (DLBCL)

    Posted on 08.08.2024

    Incyte-386x260



    The purpose of this Toolkit is to help support your experience as someone living with Diffuse Large B-Cell Lymphoma (DLBCL) or as a care partner by providing information to help you build a deeper understanding of DLBCL. This Toolkit was created by a group of patients, care partners, advocates and healthcare professionals brought together by Incyte, a pharmaceutical company working on behalf of the DLBCL community.
    View Resource



  • Implementing a Quality Intervention for Patients with Clinical Characteristics of Advanced Polycythemia Vera

    Posted on 07.30.2024

    Incyte-386x260



    This resource is a guide for pharmacy directors and clinical pharmacists to help clinicians identify the subset of patients with clinical characteristics of advanced polycythemia vera (PV).
    View Resource



  • Identifying Patients with Advanced Polycythemia Vera

    Posted on 07.30.2024

    Incyte-386x260



    This resource is a step-by-step EMR guide for appropriate US population health decision makers or similar entities and their health systems to identify the subset of patients who may have clinical characteristics of advanced polycythemia vera (PV).
    View Resource



  • What to Expect from Your Eye Care Appointments While Taking ELAHERE (mirvetuximab soravtansine-gynx)

    Posted on 07.18.2024

    ImmunoGen-380x80


    This resource is intended for patients looking to:

    • Understand what Ocular AEs may occur while on ELAHERE
    • See what to expect during eye exams
    • Review the important steps involved in proactively managing eye care while on treatment
    • Learn the importance of communicating any side effects to your care team

    Watch video



  • Best Practices for the Management of Ocular Adverse Events Associated with ELAHERE (mirvetuximab soravtansine-gynx)

    Posted on 07.18.2024

    ImmunoGen-380x80


    This resource is intended for eye doctors or oncologists looking to:

    • Understand why patients on ELAHERE require eye exams, and when
    • Learn about what ocular AEs may be experienced by patients on ELAHERE
    • Review the proactive eye drops administration patients should take during treatment
    • See resources available to help facilitate communication between eye doctors and oncologists

    Watch video



  • Help Patients Face the Realities of Life with Metastatic Breast Cancer Through Expose MBC

    Published on: July 15, 2024

    Gilead-Expose-MBC-140x59


    Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.

    Visit http://Expose-MBC.com and share this site with your patients.



  • LOQTORZI® Receives a Permanent J Code: Effective July 1, 2024

    Published on: July 2, 2024

    Coherus-250x80


    Coherus is pleased to announce CMS has granted LOQTORZI® (toripalimab-tpzi) a product-specific J Code.
    View Resource



  • ESR1 Mutations in ER+/HER2 - Metastatic Breast Cancer

    Published on: June 26, 2024

    Stemline-A-Menarini-Group-Company-320x90






    Nearly 1 out of 2 people with ER+/HER2- metastatic breast cancer may develop an ESR1 mutation after progression on hormone therapy.

    Learn more about this ESR1 mutation at http://Knowesr1.com
    .



  • Diagnosis and Treatment of Hematologic Cancer

    Published on: June 26, 2024

    Stemline-A-Menarini-Group-Company-320x90






    BPDCN
    is a cancer that affects your blood and the soft tissue inside your bones, which is called bone marrow. It can also affect other parts of your body, such as your lymph nodes, spleen, central nervous system, and skin.

    Learn more about this hematologic disease at https://BPDCNinfo.com.



  • Patient Selection Criteria and Surgical Resection Considerations when Evaluating Patients with Previously-Treated Advanced Melanoma

    Published on: June 21, 2024

    Iovance-200x80





    AMTAGVI (lifileucel) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
    View Resource